RYAH Group’s (CSE: RYAH) wholly owned subsidiary, RYAH Medtech Inc., has entered a definitively exclusive software development and product distribution agreement with its France-based partner, DelleD SAS, for the distribution of the RYAH Smart Inhaler. According to the update, the strategic agreement further defines the previously announced arrangement with DelleD to distribute RYAH Smart Inhalers in the territory of France and participate in the upcoming tender for the French government’s national experiment on patient use of medical cannabis. “In addition to distribution of the proprietary devices and accessories, the deal involves a statement of work (‘SOW’) for RYAH to develop customized software for DelleD that would cater to the French patients who intend to use and track their plant-based therapies via DelleD,” said Jordan Medley, head of Product Operations at RYAH, noting this project is the company’s second customized software development order. “Providing a robust data collection mechanism ensures more comprehensive patient feedback — and, consequently, accurate clinical trial results.”
To view the full press release, visit https://cnw.fm/SQyPi
About RYAH Group Inc.
RYAH is a big data and technology company focused on valuable predictive analysis in the global medical intake industry. The company manages a complete digital ecosystem leveraging both internet of things (“IoT”) and artificial intelligence (“AI”) to create a dynamic data service for the medical plant industry. It is developing a suite of IoT devices, including a dry-herb vaporizer device capable of storing all plant lab results, measuring patient inhalation sessions in real-time and capturing instant feedback for plant dose management. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for pharmacies, clinics, growers, dispensaries, and licensed processors (“LPs”) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption. For more information about the company, please visit www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://cnw.fm/RYAH
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CanadianCannabisWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor